Supernus Pharmaceuticals (SUPN) Equity Average (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Equity Average data on file, last reported at $1.1 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $1.1 billion, up 3.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 3.49% YoY), and the FY2025 annual result was $1.0 billion, up 7.16% from the prior year.
• Equity Average advanced to $1.1 billion in Q1 2026 per SUPN's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Equity Average peaked at $1.1 billion in Q1 2026 and troughed at $822.1 million in Q1 2022.
• A 5-year average of $950.4 million and a median of $925.3 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average climbed 2.91% in 2024, then grew 11.66% in 2025.
• A 5-year view of Equity Average shows it stood at $869.5 million in 2022, then gained by 5.45% to $916.9 million in 2023, then rose by 11.41% to $1.0 billion in 2024, then grew by 3.35% to $1.1 billion in 2025, then increased by 1.29% to $1.1 billion in 2026.
• Business Quant data shows SUPN's Equity Average at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.